These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9821294)

  • 21. Candida glabrata erg1 mutant with increased sensitivity to azoles and to low oxygen tension.
    Tsai HF; Bard M; Izumikawa K; Krol AA; Sturm AM; Culbertson NT; Pierson CA; Bennett JE
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2483-9. PubMed ID: 15215098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
    Swinne D; Watelle M; Van der Flaes M; Nolard N
    Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative sensitivity of yeasts to ketoconazole, itraconazole and fluconazole using a liquid medium standardized micromethod].
    Guinet R; Marlier H
    Pathol Biol (Paris); 1990 Jun; 38(5 ( Pt 2)):575-8. PubMed ID: 2166937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antifungal activity of Rubus chingii extract combined with fluconazole against fluconazole-resistant Candida albicans.
    Han B; Chen J; Yu YQ; Cao YB; Jiang YY
    Microbiol Immunol; 2016 Feb; 60(2):82-92. PubMed ID: 26891940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of disk diffusion test and Etest for voriconazole and fluconazole susceptibility testing.
    Buchta V; Vejsova M; Vale-Silva LA
    Folia Microbiol (Praha); 2008; 53(2):153-60. PubMed ID: 18837162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fcr1p inhibits development of fluconazole resistance in Candida albicans by abolishing CDR1 induction.
    Shen H; An MM; Wang de J; Xu Z; Zhang JD; Gao PH; Cao YY; Cao YB; Jiang YY
    Biol Pharm Bull; 2007 Jan; 30(1):68-73. PubMed ID: 17202662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss-of-function pdr3 mutations convert the Pdr3p transcription activator to a protein suppressing multidrug resistance in Saccharomyces cerevisiae.
    Sidorova M; Drobna E; Dzugasova V; Hikkel I; Subik J
    FEMS Yeast Res; 2007 Mar; 7(2):254-64. PubMed ID: 17266731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluconazole inhibits pseudohyphal growth in Saccharomyces cerevisiae.
    Kontoyiannis DP
    Chemotherapy; 2000; 46(2):100-3. PubMed ID: 10671759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Broth medium for microdilution susceptibility tests of fluconazole and voriconazole.
    Barry A; Brown S; Traczewski M
    Eur J Clin Microbiol Infect Dis; 2002 May; 21(5):407-10. PubMed ID: 12072930
    [No Abstract]   [Full Text] [Related]  

  • 31. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
    Sanglard D; Coste AT
    Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory effects of gallic acid ester derivatives on Saccharomyces cerevisiae multidrug resistance protein Pdr5p.
    Pereira Rangel L; Fritzen M; Yunes RA; Leal PC; Creczynski-Pasa TB; Ferreira-Pereira A
    FEMS Yeast Res; 2010 May; 10(3):244-51. PubMed ID: 20132313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic antifungal activity of statin-azole associations as witnessed by Saccharomyces cerevisiae- and Candida utilis-bioassays and ergosterol quantification.
    Cabral ME; Figueroa LI; Fariña JI
    Rev Iberoam Micol; 2013 Jan; 30(1):31-8. PubMed ID: 23069981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulated overexpression of CDR1 in Candida albicans confers multidrug resistance.
    Niimi M; Niimi K; Takano Y; Holmes AR; Fischer FJ; Uehara Y; Cannon RD
    J Antimicrob Chemother; 2004 Dec; 54(6):999-1006. PubMed ID: 15486081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Multisite evaluation of a colorimetric broth microdilution antifungal susceptibility testing].
    Yamane N; Igari J
    Rinsho Byori; 1997 Feb; 45(2):190-9. PubMed ID: 9121005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [In vitro pharmacological study of fluconazole. Evaluation of an antifungal assay].
    Duval F; Lavarde V
    Pathol Biol (Paris); 1993 May; 41(5):469-73. PubMed ID: 8414680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole.
    Morace G; Manzara S; Dettori G
    Chemotherapy; 1991; 37(1):23-31. PubMed ID: 2013239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid identification of fluconazole resistance using Chromagar Candida.
    Verghese SL; Padmaja P; Sutha P; Mathew T; John ES
    Indian J Pathol Microbiol; 2000 Jul; 43(3):343-6. PubMed ID: 11218683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Saccharomyces cerevisiae oesophagitis in a patient with oesophageal carcinoma.
    Kliemann DA; Antonello VS; Severo LC; Pasqualotto AC
    J Infect Dev Ctries; 2011 Jul; 5(6):493-5. PubMed ID: 21727651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of a broth microdilution antifungal susceptibility test with a pH indicator: comparison with the broth macrodilution procedures.
    Fournier C; Gaspar A; Boillot F; Villard J
    J Antimicrob Chemother; 1995 Mar; 35(3):373-80. PubMed ID: 7782253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.